A HER3-targeted antibody-drug conjugate administered IV every 3 weeks in a Phase 1 dose escalation/expansion study. It is an anti-HER3 (ERBB3) monoclonal antibody that is internalized upon binding HER3 on tumor cells and releases a topoisomerase I inhibitor payload to induce DNA damage and apoptosis.
HER3-targeted monoclonal antibody binds ERBB3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that inhibits Topo I, causing DNA damage (replication-associated strand breaks) and apoptosis.
YES
DIRECT
The HER3-targeted ADC binds ERBB3 on target cells, is internalized, and releases a topoisomerase I inhibitor payload that causes replication-associated DNA strand breaks leading to apoptosis.
A HER3-targeted antibody-drug conjugate administered IV every 3 weeks in a Phase 1 dose escalation/expansion study. It is an anti-HER3 (ERBB3) monoclonal antibody that is internalized upon binding HER3 on tumor cells and releases a topoisomerase I inhibitor payload to induce DNA damage and apoptosis.
HER3-targeted monoclonal antibody binds ERBB3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that inhibits Topo I, causing DNA damage (replication-associated strand breaks) and apoptosis.
NO
INDIRECT
SIBP-A13 targets HER3 (ERBB3) on the cell surface, is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage and apoptosis. Killing is directed by HER3 expression; topoisomerase I is the intracellular payload target, not the directly targeted antigen.
An autologous, type-1–polarized dendritic-cell vaccine pulsed with peptides from native and mutated ESR1; administered intranodally or intratumorally to present antigen via MHC I/II and prime Th1/CD8+ T-cell responses against ER/ESR1-mutant tumor cells.
Autologous type-1-polarized dendritic cells pulsed with peptides from native and mutant ESR1 are injected intranodally or intratumorally to present ESR1 epitopes via MHC class I and II, produce IL-12 to induce Th1 skewing, and prime ESR1-specific CD4+ and CD8+ T-cell responses that mediate cytotoxicity against ER/ESR1-mutant tumor cells.
YES
INDIRECT
The DC1 vaccine presents ESR1 peptides on MHC I/II and secretes IL-12 to prime ESR1-specific CD8+ and Th1 responses. Activated CTLs then recognize ESR1 peptide–MHC on tumor cells and kill them via perforin/granzyme and Fas–FasL pathways.
An autologous, type-1–polarized dendritic-cell vaccine pulsed with peptides from native and mutated ESR1; administered intranodally or intratumorally to present antigen via MHC I/II and prime Th1/CD8+ T-cell responses against ER/ESR1-mutant tumor cells.
Autologous type-1-polarized dendritic cells pulsed with peptides from native and mutant ESR1 are injected intranodally or intratumorally to present ESR1 epitopes via MHC class I and II, produce IL-12 to induce Th1 skewing, and prime ESR1-specific CD4+ and CD8+ T-cell responses that mediate cytotoxicity against ER/ESR1-mutant tumor cells.
YES
INDIRECT
Vaccine-primed ESR1-specific CD8+ T cells recognize mutant ESR1 peptide–MHC I on tumor cells and kill them via perforin/granzyme (and Fas/FasL) after Th1 polarization by IL-12–producing dendritic cells.
Anti-CD20 monoclonal antibody that depletes CD20-positive B cells via ADCC, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20-positive cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binds CD20 on B cells and induces killing via antibody-dependent cellular cytotoxicity (FcγR-expressing effector cells), complement-dependent cytotoxicity, and direct apoptosis signaling.